339 related articles for article (PubMed ID: 23125525)
1. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth.
Allard B; Turcotte M; Stagg J
J Biomed Biotechnol; 2012; 2012():485156. PubMed ID: 23125525
[TBL] [Abstract][Full Text] [Related]
2. Targeting adenosine and regulatory T cells in cancer immunotherapy.
Churov A; Zhulai G
Hum Immunol; 2021 Apr; 82(4):270-278. PubMed ID: 33610376
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
de Leve S; Wirsdörfer F; Jendrossek V
Front Immunol; 2019; 10():698. PubMed ID: 31024543
[TBL] [Abstract][Full Text] [Related]
4. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
[TBL] [Abstract][Full Text] [Related]
5. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells.
Romio M; Reinbeck B; Bongardt S; Hüls S; Burghoff S; Schrader J
Am J Physiol Cell Physiol; 2011 Aug; 301(2):C530-9. PubMed ID: 21593451
[TBL] [Abstract][Full Text] [Related]
6. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
[TBL] [Abstract][Full Text] [Related]
7. CD73 and adenosine generation in the creation of regulatory microenvironments.
Regateiro FS; Cobbold SP; Waldmann H
Clin Exp Immunol; 2013 Jan; 171(1):1-7. PubMed ID: 23199317
[TBL] [Abstract][Full Text] [Related]
8. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
[No Abstract] [Full Text] [Related]
9. [Immune regulation via the generation of extracellular adenosine by CD73].
Tsukamoto H
Seikagaku; 2014 Dec; 86(6):766-9. PubMed ID: 25675814
[No Abstract] [Full Text] [Related]
10. Enzyme activity of circulating CD73 in human serum.
Morello S; Turiello R; Madonna G; Pinto A; Ascierto PA; Capone M
Methods Enzymol; 2019; 629():257-267. PubMed ID: 31727244
[TBL] [Abstract][Full Text] [Related]
11. CD73-mediated adenosine production promotes stem cell-like properties in mouse Tc17 cells.
Flores-Santibáñez F; Fernández D; Meza D; Tejón G; Vargas L; Varela-Nallar L; Arredondo S; Guixé V; Rosemblatt M; Bono MR; Sauma D
Immunology; 2015 Dec; 146(4):582-94. PubMed ID: 26331349
[TBL] [Abstract][Full Text] [Related]
12. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
13. Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape.
Ghiringhelli F; Bruchard M; Chalmin F; Rébé C
J Biomed Biotechnol; 2012; 2012():473712. PubMed ID: 23133312
[TBL] [Abstract][Full Text] [Related]
14. The Immune Regulatory Role of Adenosine in the Tumor Microenvironment.
Xing J; Zhang J; Wang J
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834375
[TBL] [Abstract][Full Text] [Related]
15. CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression.
Schneider E; Winzer R; Rissiek A; Ricklefs I; Meyer-Schwesinger C; Ricklefs FL; Bauche A; Behrends J; Reimer R; Brenna S; Wasielewski H; Lauten M; Rissiek B; Puig B; Cortesi F; Magnus T; Fliegert R; Müller CE; Gagliani N; Tolosa E
Nat Commun; 2021 Oct; 12(1):5911. PubMed ID: 34625545
[TBL] [Abstract][Full Text] [Related]
16. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
[TBL] [Abstract][Full Text] [Related]
17. An IL6-Adenosine Positive Feedback Loop between CD73
Hu G; Cheng P; Pan J; Wang S; Ding Q; Jiang Z; Cheng L; Shao X; Huang L; Huang J
Cancer Immunol Res; 2020 Oct; 8(10):1273-1286. PubMed ID: 32847938
[TBL] [Abstract][Full Text] [Related]
18. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
20. The roles of CD73 in cancer.
Gao ZW; Dong K; Zhang HZ
Biomed Res Int; 2014; 2014():460654. PubMed ID: 25126561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
